Objectives:To develop the List of Clinical Needs for New Chinese Materia Medica Development(Second Batch),aiming to identify and highlight specific diseases with pressing,unmet therapeutic needs.The objective is to gu...Objectives:To develop the List of Clinical Needs for New Chinese Materia Medica Development(Second Batch),aiming to identify and highlight specific diseases with pressing,unmet therapeutic needs.The objective is to guide pharmaceutical research and development(R&D)by establishing development priorities based on clinical gaps,epidemiological burden,and the shortcomings of existing treatments.Methods:The list was developed by the China Association of Chinese Medicine using a methodology grounded in evidence and expert consensus.Results:The list identifies 8 diseases with significant clinical gaps:Myelodysplastic syndromes(MDS),fibromyalgia(FM),atrophic gastritis and its precancerous lesions,adenomyosis(AM),diabetes related foot ulcers(DFU),granulomatous mastitis(GLM),diabetic kidney disease(DKD),and metabolic-associated fatty liver disease(MAFLD).For each disease,the list provides a systematic analysis of epidemiological burden,limitations of current treatments,and specific clinical needs.It also proposes a strategic research framework focused on multi-target mechanisms,disease-modifying potential,and optimized combination therapies.Conclusions:The list provides a strategically structured framework to guide the development of new Chinese materia medica.It aligns traditional Chinese medicine(TCM)development with national public health priorities,emphasizes TCM's holistic and multi-target advantages,and promotes a patient-centered approach.By bridging clinical needs with TCM principles,the list aims to foster the creation of clinically valuable medicines to address chronic and complex diseases where current western medical approaches are insufficient.展开更多
With the interdisciplinary convergence of biology,medicine and materials science,both research and clinical translation of biomaterials are progressing at a rapid pace.However,there is still a huge gap between applied...With the interdisciplinary convergence of biology,medicine and materials science,both research and clinical translation of biomaterials are progressing at a rapid pace.However,there is still a huge gap between applied basic research on biomaterials and their translational products-medical devices,where two significantly different perspectives and mindsets often work independently and non-synergistically,which in turn significantly increases financial costs and research effort.Although this gap is well-known and often criticized in the biopharmaceutical industry,it is gradually widening.In this article,we critically examine the developmental pipeline of biodegradable biomaterials and biomaterial-based medical device products.Then based on clinical needs,market analysis,and relevant regulations,some ideas are proposed to integrate the two different mindsets to guide applied basic research and translation of biomaterial-based products,from the material and technical perspectives.Cartilage repair substitutes are discussed here as an example.Hopefully,this will lay a strong foundation for biomaterial research and clinical translation,while reducing the amount of extra research effort and funding required due to the dissonance between innovative basic research and commercialization pipeline.展开更多
Biomaterials and materiobiology are revolutionizing the approaches to solving aging-related medical challenges.With our society facing increasing aging-related diseases such as cancer,osteoporosis,Alzheimer's dise...Biomaterials and materiobiology are revolutionizing the approaches to solving aging-related medical challenges.With our society facing increasing aging-related diseases such as cancer,osteoporosis,Alzheimer's disease,Parkinson's disease,diabetes,and cardiovascular diseases,interdisciplinary efforts are crucial to connect material design,biological insights,and clinical unmet needs.展开更多
文摘Objectives:To develop the List of Clinical Needs for New Chinese Materia Medica Development(Second Batch),aiming to identify and highlight specific diseases with pressing,unmet therapeutic needs.The objective is to guide pharmaceutical research and development(R&D)by establishing development priorities based on clinical gaps,epidemiological burden,and the shortcomings of existing treatments.Methods:The list was developed by the China Association of Chinese Medicine using a methodology grounded in evidence and expert consensus.Results:The list identifies 8 diseases with significant clinical gaps:Myelodysplastic syndromes(MDS),fibromyalgia(FM),atrophic gastritis and its precancerous lesions,adenomyosis(AM),diabetes related foot ulcers(DFU),granulomatous mastitis(GLM),diabetic kidney disease(DKD),and metabolic-associated fatty liver disease(MAFLD).For each disease,the list provides a systematic analysis of epidemiological burden,limitations of current treatments,and specific clinical needs.It also proposes a strategic research framework focused on multi-target mechanisms,disease-modifying potential,and optimized combination therapies.Conclusions:The list provides a strategically structured framework to guide the development of new Chinese materia medica.It aligns traditional Chinese medicine(TCM)development with national public health priorities,emphasizes TCM's holistic and multi-target advantages,and promotes a patient-centered approach.By bridging clinical needs with TCM principles,the list aims to foster the creation of clinically valuable medicines to address chronic and complex diseases where current western medical approaches are insufficient.
基金This work was supported by the National Natural Science Foundation of China grant(81772334).
文摘With the interdisciplinary convergence of biology,medicine and materials science,both research and clinical translation of biomaterials are progressing at a rapid pace.However,there is still a huge gap between applied basic research on biomaterials and their translational products-medical devices,where two significantly different perspectives and mindsets often work independently and non-synergistically,which in turn significantly increases financial costs and research effort.Although this gap is well-known and often criticized in the biopharmaceutical industry,it is gradually widening.In this article,we critically examine the developmental pipeline of biodegradable biomaterials and biomaterial-based medical device products.Then based on clinical needs,market analysis,and relevant regulations,some ideas are proposed to integrate the two different mindsets to guide applied basic research and translation of biomaterial-based products,from the material and technical perspectives.Cartilage repair substitutes are discussed here as an example.Hopefully,this will lay a strong foundation for biomaterial research and clinical translation,while reducing the amount of extra research effort and funding required due to the dissonance between innovative basic research and commercialization pipeline.
文摘Biomaterials and materiobiology are revolutionizing the approaches to solving aging-related medical challenges.With our society facing increasing aging-related diseases such as cancer,osteoporosis,Alzheimer's disease,Parkinson's disease,diabetes,and cardiovascular diseases,interdisciplinary efforts are crucial to connect material design,biological insights,and clinical unmet needs.
